Ticker
ABEO

Price
2.40
Stock movement down
-0.05 (-2.04%)
Company name
Abeona Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
41.22M
Ent value
58.84M
Price/Sales
9.48
Price/Book
2.67
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
727.59%
3 year return
4.06%
5 year return
-30.24%
10 year return
-20.25%
Last updated: 2023-03-22
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
March 29, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
December 1, 2022

iO Charts is a Seeking Alpha partner

DIVIDENDS

ABEO does not pay dividends or no data was received
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
November 14, 2022

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
November 3, 2022

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales9.48
Price to Book2.67
EV to Sales13.54
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
November 3, 2022

iO Charts is a Seeking Alpha partner

Results from the pivotal VITAL study, using EB-101 for the treatment of patients with RDEB are expected to be released before the end of 2022. Read more here.
October 19, 2022

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count17.18M
EPS (TTM)-13.28
FCF per share (TTM)-7.64

Income statement

Loading...
Income statement data
Revenue (TTM)4.35M
Gross profit (TTM)4.00M
Operating income (TTM)-84.63M
Net income (TTM)-85.25M
EPS (TTM)-13.28
EPS (1y forward)-1.79

Margins

Loading...
Margins data
Gross margin (TTM)91.95%
Operating margin (TTM)-1947.33%
Profit margin (TTM)-1961.64%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash5.73M
Net receivables1.05M
Total current assets25.50M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets38.76M
Accounts payable1.75M
Short/Current long term debt8.29M
Total current liabilities12.60M
Total liabilities23.35M
Shareholder's equity15.41M
Net tangible assets15.41M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-46.16M
Capital expenditures (TTM)2.91M
Free cash flow (TTM)-49.07M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-553.12%
Return on Assets-219.95%
Return on Invested Capital-495.00%
Cash Return on Invested Capital-284.93%
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
October 4, 2022

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
October 3, 2022

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open2.46
Daily high2.49
Daily low2.38
Daily Volume49K
All-time high47188.00
1y analyst estimate21.33
Beta1.25
EPS (TTM)-13.28
Dividend per share-
Ex-div date22 Jul 2022
Next earnings date29 Mar 2023

Downside potential

Loading...
Downside potential data
ABEOS&P500
Current price drop from All-time high-99.99%-17.92%
Highest price drop-100.00%-56.47%
Date of highest drop17 Jun 20229 Mar 2009
Avg drop from high-92.06%-11.51%
Avg time to new high406 days13 days
Max time to new high7600 days1805 days
The following slide deck was published by Abeona Therapeutics Inc.
August 17, 2022

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
August 11, 2022

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ABEO (Abeona Therapeutics Inc) company logo
Marketcap
41.22M
Marketcap category
Small-cap
Description
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Employees
90
Investor relations
-
SEC filings
CEO
Joao Siffert
Country
USA
City
New York
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
July 20, 2022

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
July 5, 2022

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
May 19, 2022

iO Charts is a Seeking Alpha partner

Abeona Therapeutics Inc. (NASDAQ:NASDAQ:ABEO) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ETCompany ParticipantsVishwas Seshadri - Chief Executive OfficerJoseph Vazzano - Chief...
May 17, 2022

iO Charts is a Seeking Alpha partner

COMPANY NEWS
All newsPress releases
We can readily understand why investors are attracted to unprofitable companies. For example, although...
March 31, 2023
Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase 3 VIITAL™ study results announced in 4Q 2022 Advancing AAV-based gene therapy candidates toward IND studies in ...
March 29, 2023
NEW YORK and CLEVELAND, March 24, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new employees who joined Abeona. On March 23, 2023, A...
March 24, 2023
NEW YORK and CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that additional data from its pivotal Phase 3 VIITAL™ study of EB-101 for recessive d...
March 16, 2023
Advancing AAV-based gene therapy candidates toward IND studies on encouraging animal proof of concept data in Stargardt Disease, X-linked Retinoschisis (XLRS), and Autosomal Dominant Optic Atrophy (AD...
March 14, 2023
Following positive topline data from Phase 3 VIITAL™ study of EB-101 with both co-primary endpoints met, Abeona plans to submit BLA to U.S. FDA in 2Q 2023 Company well-funded with expected cash runway...
November 14, 2022
Cantor Fitzgerald raised the price target on Abeona Therapeutics Inc (NASDAQ: ABEO) from $22 to $40 after adjusting the market model/ increasing the probability of success for EB-101. Last week, the c...
November 8, 2022
Abeona Therapeutics Inc (NASDAQ: ABEO) announced topline data from its pivotal Phase 3 VIITAL study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB). The VIITAL study met its two co-pri...
November 3, 2022
NEW YORK and CLEVELAND, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) announced today that it has entered into a securities purchase agreement to sell 7,065,946 shares of i...
November 3, 2022
Co-primary endpoint measuring >50% wound healing, other endpoints measuring >75% and complete wound healing at six months all met Co-primary endpoint measuring pain reduction at six months met; greate...
November 3, 2022
Next page
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
May 17, 2022

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
May 13, 2022

iO Charts is a Seeking Alpha partner